Literature DB >> 4561333

Clinical trial of 2-Br- -ergocryptine (CB154) in advanced breast cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4561333     DOI： 10.1016/0014-2964(72)90037-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  10 in total

1.  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Authors:  A Manni; A E Boucher; L M Demers; H A Harvey; A Lipton; M A Simmonds; M Bartholomew
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

Review 2.  Prolactin as an autocrine/paracrine factor in breast tissue.

Authors:  C V Clevenger; T L Plank
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

Review 3.  Pharmacology of bromocriptine in health and disease.

Authors:  A E Mehta; G Tolis
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

4.  Treatment of benign breast disease with bromocriptine.

Authors:  A Mussa; L Dogliotti
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

5.  Characterization of prolactin receptors in human breast cancer.

Authors:  J P Peyrat; J Djiane; P A Kelly; B Vandewalle; J Bonneterre; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

6.  Primate mammary development. Effects of hypophysectomy, prolactin inhibition, and growth hormone administration.

Authors:  D L Kleinberg; W Niemann; E Flamm; P Cooper; G Babitsky; Q Valensi
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

7.  Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development.

Authors:  W Ruan; C B Newman; D L Kleinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

8.  Season of tumour detection influences factors predicting survival of patients with breast cancer.

Authors:  B H Mason; I M Holdaway; A W Stewart; L M Neave; R G Kay
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

9.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop.

Authors:  C V Clevenger; W P Chang; W Ngo; T L Pasha; K T Montone; J E Tomaszewski
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

Review 10.  From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.

Authors:  Charles V Clevenger; Jiamao Zheng; Elizabeth M Jablonski; Traci L Galbaugh; Feng Fang
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.